J&J downsizes infectious disease and vaccine pipeline, cutting hepatitis B programs
2023-07-20
临床2期临床结果siRNA
Johnson & Johnson has culled seven programs from its infectious disease pipeline since the first quarter of the year, most of which are hepatitis B therapies, as part of a “prioritization” of its R&D business.
In the Big Pharma’s second quarter earnings report on Thursday, its pipeline no longer includes experimental treatments for hepatitis B and D, flu, and some HIV candidates.
J&J had been testing JNJ-3989, a combo therapy for hepatitis B and a hepatitis B and D co-infection in Phase II trials. JNJ-7744 and JNJ-3283 were both in Phase I for hepatitis B, while JNJ-0953 was in Phase II for influenza.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。